Reuters logo
BRIEF-Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets
September 21, 2017 / 11:47 AM / 3 months ago

BRIEF-Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets

Sept 21 (Reuters) - Provention Bio Inc

* Provention Bio announces licensing agreements with Janssen for two clinical-stage immunology assets

* Provention Bio​ says ‍entered into agreements with Janssen Pharmaceutica NV, Janssen Sciences Ireland UC to in-license 2 clinical-stage assets

* ‍Provention Bio -PRV-6527 to be studied in phase 2a POC clinical trial in Crohn’s disease,for which Provention anticipates initiating enrollment in H1 2018​ Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below